Newsroom

LATEST PUBLICATIONS

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

2021-02-17T18:10:07-08:00November 17th, 2020|

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

2021-02-11T20:05:42-08:00October 30th, 2020|

Plasticity of the human IgM repertoire in response to long‐term spaceflight

2021-02-11T20:09:45-08:00October 13th, 2020|

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

2021-02-11T20:11:02-08:00October 8th, 2020|

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

2021-02-11T20:13:51-08:00August 27th, 2020|

Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan

2021-02-26T19:11:48-08:00November 19th, 2018|

Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)

2025-11-26T15:29:44-08:00September 27th, 2018|

Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels

2021-02-26T19:12:15-08:00May 9th, 2018|

Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

2021-02-26T19:12:23-08:00May 8th, 2018|

Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software

2021-02-26T19:12:40-08:00November 7th, 2017|

AMP

Nov 10-14, 2026
Seattle, WA
Exhibiting
Visit Conference Website

68th Japanse Society of Pediatric Hematology/ Oncology

Nov 12 – 14, 2026
Yokohama, Japan
Attending

Medica

Nov 16-19, 2026
Dusseldorf, Germany
Attending
Visit Conference Website

49th the Molecular Biology Society of Japan

Dec 1 – 4, 2026
Yokohama, Japan
Attending

ASH

Dec 12-15, 2026
New Orleans, LA
Exhibiting
Visit Conference Website

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Newsroom

Newsroom

LATEST PUBLICATIONS

LATEST PRESS

CONFERENCES

AMP

68th Japanse Society of Pediatric Hematology/ Oncology

Medica

49th the Molecular Biology Society of Japan

ASH

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.